An Open Label, Single Arm, Multicentre Study to Assess the Clinical Efficacy and Safety of Lynparza (Olaparib) Tablets Maintenance Monotherapy in Platinum Sensitive Relapsed Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (L-MOCA)
Phase of Trial: Phase III
Latest Information Update: 30 Dec 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms L-MOCA
- Sponsors AstraZeneca
- 11 Jun 2018 Planned End Date changed from 3 May 2022 to 1 Mar 2022.
- 11 Jun 2018 Planned primary completion date changed from 3 May 2022 to 1 Mar 2022.
- 11 Jun 2018 Status changed from not yet recruiting to recruiting.